Androgenetic Alopecia Treatment Market - By Treatment Type (Pharmaceutical {Topical, Oral}, Device {Laser Cap, Comb, Helmet}), By Gender (Male, Female), By Medication Type (Prescription, OTC), By End-use & Forecast, 2024 – 2032

Androgenetic Alopecia Treatment Market Size

Androgenetic Alopecia Treatment Market size was valued at around USD 2.8 billion in 2023 and is estimated to grow at 7.6% CAGR from 2024 to 2032. The increasing incidence of androgenetic alopecia is fueled by various factors such as changing lifestyle patterns, genetic predisposition, and hormonal imbalances, all contributing significantly to the market growth. For instance, the National Library of Medicine states that androgenetic alopecia affects up to 50 million men in the U.S.
 

Furthermore, the increasing prevalence of chronic diseases associated with hair loss is a significant factor driving the demand for market. The condition is often associated with chronic diseases such as diabetes, hypertension, asthma, and polycystic ovarian syndrome (PCOS). For instance, the prevalence of hypertension in the U.S. in 2021 was 49.6% corresponding to 115 million persons. Hence, the market is expected to grow significantly in the coming years due to the rising incidence of these conditions and the increasing demand for effective solutions to address hair loss concerns.
 

Androgenetic alopecia treatment refers to interventions aimed at managing androgenetic alopecia, a common form of hair loss characterized by a genetic predisposition and hormonal influences. The treatment aims to slow down hair loss, promote hair regrowth, and improve overall hair density and appearance.
 

Androgenetic Alopecia Treatment Market Trends

Advancements in AGA treatment has been facilitated by understanding the functions and interactions of key components. This comprehension enables researchers to pinpoint drug targets and design drugs with precision, potentially boosting efficacy and safety. These advancements have led to the development of more effective treatment strategies, driving market growth.  
 

• Technological advancements have led to the development of more effective treatments for AGA. For instance, the introduction of topical formulations with enhanced penetration capabilities allows for better delivery of active ingredients like minoxidil and finasteride to the hair follicles, thereby improving treatment efficacy. Moreover, the discovery of the structure of type 2, 5-alpha reductase (SRD5A2) in 2020 has opened new possibilities for developing more effective hair treatments. This breakthrough has shown better potential and possibilities for treating other diseases as well.  
   
• Another promising treatment is clascoterone, an FDA-approved topical androgen receptor inhibitor initially used for acne. Recent studies indicate clascoterone's potential effectiveness in treating AGA, with patients treated with clascoterone 7.5% twice daily for 6 months experiencing reduced hair loss and improvement.
   
• Advancements in digital health technologies, such as mobile applications and telemedicine platforms, have facilitated remote monitoring and management of AGA patients. These advancements offer improved treatment options for androgenetic alopecia, especially for females and younger males.

Androgenetic Alopecia Treatment Market Analysis

Based on treatment type, the market is categorized into pharmaceutical, device and other treatment types. The pharmaceutical segment dominates the market with a revenue of around USD 1.4 billion in 2023.
 

• Clinical studies and real-world evidence have demonstrated the effectiveness of pharmaceutical treatments in slowing down hair loss and promoting hair regrowth in individuals with androgenetic alopecia. This evidence-based approach has contributed to the widespread adoption of these treatments.
   
• Additionally, pharmaceutical treatments available in various forms such as topical formulations like topical antibiotics and oral medications offer convenience to patients, further contributing to the growing demand for pharmaceuticals to treat androgenetic alopecia.
   

Based on gender, the androgenetic alopecia treatment market is categorized into male and female. The male segment dominates the market with a revenue of around USD 1.9 billion in 2023.
 

• Androgenetic alopecia is more common in men than in women, typically affecting men at an earlier age and progressing more rapidly. This leads to a higher proportion of affected males seeking treatment.
   
• Additionally, male-pattern baldness, the most common form of androgenetic alopecia in men, can significantly impact self-esteem and social perceptions of masculinity. As a result, men may be more motivated to seek treatment for hair loss compared to women.
   

Based on medication type, the androgenetic alopecia treatment market is categorized into prescription and OTC. The prescription segment held a majority market share with a revenue of around USD 1.8 billion in 2023.
 

• Prescription medications for androgenetic alopecia are typically prescribed by healthcare providers, such as dermatologists, general practitioners, or hair restoration specialists. Patients often seek professional medical advice and treatments for their hair loss, leading to a higher proportion of sales through prescription channels.
   
• Furthermore, some health insurance plans may cover prescription medications for androgenetic alopecia. This coverage can reduce out-of-pocket costs for patients, making it more likely for them to obtain these medications through prescription channels.

Based on end-use, the androgenetic alopecia treatment market is categorized into dermatology clinics, homecare settings and other end users. The dermatology clinics segment held a leading market share of around 50% in 2023.
 

• Dermatology clinics offer a wide range of treatment options. Having access to multiple treatment modalities enables dermatologists to customize treatment plans including dermatology drugs and devices based on individual patient needs and preferences.
   
• Moreover, dermatology clinics provide continuity of care for individuals with androgenetic alopecia, allowing patients to establish long-term relationships with their dermatologists and receive ongoing monitoring and management of their condition.

North America androgenetic alopecia treatment market accounted for USD 943 million revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• There is a growing awareness of androgenetic alopecia treatment options among both healthcare providers and the general population in North America. This heightened awareness is driven by several factors, including extensive educational campaigns, advocacy efforts, and advancements in medical research.
   
• Additionally, hair loss and its impact on quality of life among the general population in the region is another factor influencing the people to opt for these treatments. With an emphasis on appearance and self-image, individuals affected by androgenetic alopecia are increasingly seeking out treatment options to address their hair loss concerns.
   

The U.S. held a dominant position in the North America androgenetic alopecia treatment market, with a revenue of USD 883.2 million in 2023.
 

• Advancements in medical research have contributed significantly to increased awareness of androgenetic alopecia treatment options in the U.S.
   
• Clinical studies, scientific conferences, and publications in medical journals serve to highlight the efficacy and safety of various treatment modalities, fostering confidence among healthcare providers and patients alike.
   

Japan androgenetic alopecia treatment market is anticipated to witness substantial growth during the forecast period.
 

• Key players and research institutes in Japan are showing a growing interest in developing new products and treatments for androgenetic alopecia. This interest is driving advancements in technologies and contributing to the expansion of the market.
   
• Furthermore, Japanese companies have developed advanced hair loss treatments, such as topical formulations, low-level laser therapy devices, and hair transplantation techniques, which cater to the local demand for effective and minimally invasive solutions.
   

China exhibits a high growth potential in the androgenetic alopecia treatment market.
 

• The market is being propelled by the surge in the prevalence of alopecia (hair loss) in China, with an estimated 240 million individuals affected by various forms of alopecia.
   
• This high prevalence indicates a significant market potential for treatments targeting hair loss conditions like androgenetic alopecia.
   

Androgenetic Alopecia Treatment Market Share

The androgenetic alopecia treatment industry is fragmented in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel treatment types with improved efficiency and cost-effectiveness are key market strategies for market players, driving competition and innovation in the industry. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for advanced androgenetic alopecia treatment.
 

Androgenetic Alopecia Treatment Companies

Some of the eminent market participants operating in the androgenetic alopecia treatment industry include:

• Apira Science, Inc. (iGROW Laser)
• Aurobindo Pharma
• Cipla, Inc.
• Curallux, LLC
• Dr. Reddy’s Laboratories Ltd.
• Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
• Johnson & Johnson Services, Inc.
• Lexington Intl., LLC
• Merck & Co., Inc.
• Theradome Inc.
   

Androgenetic Alopecia Treatment Industry News:

• In November 2022, Capillus launched the Capillus MD, described as the most powerful hair restoration cap. This product launch improved the company's reputation in the market and created new sales avenues.
   
• In September 2021, Dr. Reddy's Laboratories launched a drug for women's hair loss in India, marking the first-ever approval for the treatment of female pattern hair loss (FPHL) in the country. This approval improved the company’s market presence in the market and enabled them to expand their customer base.
   

Androgenetic alopecia treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Pharmaceuticals      
  • Topical
  • Oral
• Devices        
  • Laser cap
  • Laser comb
  • Laser helmet
• Other treatment types

By Gender   

• Male  
• Female         

By Medication Type          

• Prescription
• OTC   

By End-use

• Dermatology clinics  
• Homecare settings   
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa